Tacrolimus in the treatment of idiopathic nephrotic syndrome

Expert Opinion on Investigational Drugs

Volumn 16, Issue 7, 2007, Pages 1099-1110

  Westhoff, Timm H ^a   van der Giet, Markus ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Calcineurin inhibitor; Nephrotic syndrome; Steroid dependence; Steroid resistance; Tacrolimus

Indexed keywords

AMINOGLYCOSIDE DERIVATIVE; AMPHOTERICIN B; AZATHIOPRINE; CARBAMAZEPINE; CORTICOSTEROID; COTRIMOXAZOLE; CREATININE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; CYTOTOXIC AGENT; DILTIAZEM; HYPERICUM PERFORATUM EXTRACT; INDINAVIR; MACROLIDE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NICARDIPINE; NIFEDIPINE; NONSTEROID ANTIINFLAMMATORY AGENT; ORAL CONTRACEPTIVE AGENT; PHENOBARBITAL; PHENYTOIN; PREDNISOLONE; PREDNISONE; PYRROLE DERIVATIVE; RIFAMPICIN; RITONAVIR; SAQUINAVIR; TACROLIMUS; UNINDEXED DRUG; VERAPAMIL;

ALBUMIN BLOOD LEVEL; ANEMIA; ANOREXIA; BIOAVAILABILITY; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CRYSTAL STRUCTURE; DIALYSIS; DIARRHEA; DOSE KIDNEY FUNCTION RELATION; DOSE LIVER FUNCTION RELATION; DRUG ABSORPTION; DRUG BILE LEVEL; DRUG BLOOD LEVEL; DRUG CAPSULE; DRUG CHOICE; DRUG DISTRIBUTION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG FECES LEVEL; DRUG HALF LIFE; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG STRUCTURE; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; FETUS CIRCULATION; FOCAL GLOMERULOSCLEROSIS; FOOD; FOOD DRUG INTERACTION; GLOMERULUS FILTRATION RATE; GLUCOSE BLOOD LEVEL; HEMOLYTIC UREMIC SYNDROME; HUMAN; HYPERTENSION; IDIOPATHIC DISEASE; IMMUNOSUPPRESSIVE TREATMENT; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY DYSFUNCTION; LOW DRUG DOSE; LYMPHOCYTE FUNCTION; LYMPHOCYTE PROLIFERATION; MEMBRANOUS GLOMERULONEPHRITIS; MINIMAL CHANGE GLOMERULONEPHRITIS; MONOTHERAPY; NAUSEA; NAUSEA AND VOMITING; NEPHROTIC SYNDROME; NEPHROTOXICITY; NONHUMAN; PATHOGENESIS; PROTEINURIA; RECURRENT DISEASE; REMISSION; REVIEW; SEPSIS; SIDE EFFECT; SYSTOLIC BLOOD PRESSURE; T LYMPHOCYTE ACTIVATION; TREATMENT INDICATION; TREATMENT RESPONSE;

ADULT; BIOPSY, NEEDLE; CHILD, PRESCHOOL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUGS, INVESTIGATIONAL; FEMALE; FOLLOW-UP STUDIES; GRAFT REJECTION; HUMANS; IMMUNOHISTOCHEMISTRY; IMMUNOSUPPRESSIVE AGENTS; KIDNEY FUNCTION TESTS; KIDNEY TRANSPLANTATION; MALE; MAXIMUM TOLERATED DOSE; NEPHROTIC SYNDROME; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; TACROLIMUS; TRANSPLANTATION IMMUNOLOGY; TREATMENT OUTCOME;

EID: 34447530705     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.16.7.1099     Document Type: Review

References (100)

1. MEYRIER A: Minimal change and focal-segmental glomerular sclerosis. Oxford Textbook of Clin. Nephrol. (3rd edition). Cameron S, Grunfeld JP, Ponticelli C, Von Ypersele C, Ritz E (Eds), Davison AMA, Oxford, UK (2005).
2. HAAS M, MEEHAN SM, KARRISON TG, SPARGO BH: Changing etiologies of unexplained adult nephrotic syndrome: a comparison of renal biopsy findings from 1976-1979 and 1995-1997. Am J. Kidney Dis. (1997) 30(5):621-631.
3. KORBET SM, SCHWARTZ MM, LEWIS EJ: Primary focal segmental glomerulosclerosis: clinical course and response to therapy. Am. J. Kidney Dis. (1994) 23(6):773-783.
4. CATTRAN DC, APPEL GB, HEBERT LA et al.: A randomized trial of cyclosporine in patients with steroid-resistant focal segmental glomerulosclerosis. North America Nephrotic Syndrome Study Group. Kidney Int. (1999) 56(6):2220-2226.
5. NOLASCO F, CAMERON JS, HEYWOOD EF, HICKS J, OGG C, WILLIAMS DG: Adult-onset minimal change nephrotic syndrome: a long-term follow-up. Kidney Int. (1986) 29(6):1215-1223.
6. FUJIMOTO S, YAMAMOTO Y, HISANAGA S, MORITA S, ETO T, TANAKA K: Minimal change nephrotic syndrome in adults: response to corticosteroid therapy and frequency of relapse. Am. J. Kidney Dis. (1991) 17(6):687-692.
7. RYDEL JJ, KORBET SM, BOROK RZ, SCHWARTZ MM: Focal segmental glomerular sclerosis in adults: presentation, course, and response to treatment. Am J. Kidney Dis. (1995) 25(4):534-542.
8. CHUN MJ, KORBET SM, SCHWARTZ MM, LEWIS EJ: Focal segmental glomerulosclerosis in nephrotic adults: presentation, prognosis, and response to therapy of the histologic variants. J. Am. Soc. Nephrol. (2004) 15(8):2169-2177.
9. CATTRAN DC, DELMORE T, ROSCOE J et al.: A randomized controlled trial of prednisone in patients with idiopathic membranous nephropathy. N. Engl. J. Med. (1989) 320(4):210-215.
10. CAMERON JS, HEALY MJ, ADU D: The Medical Research Council trial of short-term high-dose alternate day prednisolone in idiopathic membranous nephropathy with nephrotic syndrome in adults. The MRC Glomerulonephritis Working Party. QJ Med. (1990) 74(274):133-156.
11. BRAUN MC, WEST CD, STRIFE CF: Differences between membranoproliferative glomerulonephritis types I and III in long-term response to an alternate-day prednisone regimen. Am. J. Kidney Dis. (1999) 34(6):1022-1032.
12. BERNS JS, GAUDIO KM, KRASSNER LS et al.. Steroid-responsive nephrotic syndrome of childhood: a long-term study of clinical course, histopathology, efficacy of cyclophosphamide therapy, and effects on growth. Am. J. Kidney Dis. (1987) 9(2):108-114.
13. SCHULMAN SL, KAISER BA, POLINSKY MS, SRINIVASAN R, BALUARTE HJ: Predicting the response to cytotoxic therapy for childhood nephrotic syndrome: superiority of response to corticosteroid therapy over histopathologic pattems. J. Pediatr. (1988) 113(6):996-1001.
14. KALDOR JM, DAY NE, PETTERSSON F et al.: Leukemia following chemotherapy for ovarian cancer. N. Engl. J. Med. (1990) 322 (1):1-6.
15. ABRAMOWICZ M, BARNETT HL, EDELMANN CM Jr et al.: Controlled trial of azathioprine in children with nephrotic syndrome. A report for the international study of kidney disease in children. Lancet (1970) 1(7654):959-961.
16. BRIGGS WA, CHOI MJ, SCHEEL PJ Jr. Successful mycophenolate mofetil treatment of glomerular disease. Am. J. Kidney Dis. (1998) 31(2):213-217.
17. CHOI MJ, EUSTACE JA, GIMENEZ LF et al.: Mycophenolate mofetil treatment for primary glomerular diseases. Kidney Int. (2002) 61(3):1098-114.
18. DAY CJ, COCKWELL P, LIPKIN GW, SAVAGE CO, HOWIE AJ, ADU D: Mycophenolate mofetil in the treatment of resistant idiopathic nephrotic syndrome. Nephrol. Dial. Transplant. (2002) 17(11):2011-2013.
19. MELOCOTON TL, KAMIL ES, COHEN AH, FINE RN: Long-term cyclosporine A treatment of steroid-resistant and steroid-dependent nephrotic syndrome. Am J. Kidney Dis. (1991) 18(5):583-588.
20. MEYRIER A, NOEL LH, AURICHE P, CALLARD P: Long-term renal tolerance of cyclosporin A treatment in adult idiopathic nephrotic syndrome. Collaborative Group of the Societe de Nephrologie. Kidney Int. (1994) 45(5):1446-1456.
21. TEJANI AT, BUTT K, TRACHTMAN H, SUTHANTHIRAN M, ROSENTHAL CJ, KHAWAR MR: Cyclosporine A induced remission of relapsing nephrotic syndrome in children. Kidney Int. (1988) 33(3):729-734.
22. PONTICELLI C, EDEFONTI A, GHIO L et al.: Cyclosporin versus cyclophosphamide for patients with steroid-dependent and frequently relapsing idiopathic nephrotic syndrome: a multicentre randomized controlled trial. Nephrol. Dial. Transplant. (1993) 8(12):1326-1332.
23. NIAUDET P: Comparison of cyclosporin and chlorambucil in the treatment of steroid-dependent idiopathic nephrotic syndrome: a multicentre randomized controlled trial. The French Society of Paediatric Nephrology. Pediatr. Nephrol. (1992) 6(1):1-3.
24. MEYRIER A: Treatment of idiopathic nephrosis by immunophillin modulation. Nephrol. Dial. Transplant. (2003) 18(Suppl. 6):vi79-vi86.
25. CATTRAN DC, RAO P: Long-term outcome in children and adults with classic focal segmental glomerulosclerosis. Am. J. Kidney Dis. (1998) 32(1):72-79.
26. BANFI G, MORIGGI M, SABADINI E, FELLIN G, D'AMICO G, PONTICELLI C: The impact of prolonged immunosuppression on the outcome of idiopathic focal-segmental glomerulosclerosis with nephrotic syndrome in adults. A collaborative retrospective study. Clin. Nephrol. (1991) 36(2):53-59.
27. HEERING P, BRAUN N, MULLEJANS R et al.: Cyclosporine A and chlorambucil in the treatment of idiopathic focal segmental glomerulosclerosis. Am. J. Kidney Dis. (2004) 43(1):10-18.
28. MONTANE B, ABITBOL C, CHANDAR J, STRAUSS J, ZILLERUELO G: Novel therapy of focal glomerulosclerosis with mycophenolate and angiotensin blockade. Pediatr. Nephrol. (2003) 18(8):772-777.
29. LIEBERMAN KV, TEJANI A: A randomized double-blind placebo-controlled trial of cyclosporine in steroid-resistant idiopathic focal segmental glomerulosclerosis in children. J. Am. Soc. Nephrol. (1996) 7(1):56-63.
30. NIAUDET P: Treatment of childhood steroid-resistant idiopathic nephrosis with a combination of cyclosporine and prednisone. French Society of Paediatric Nephrology. J. Pediatr. (1994) 125(6 Part 1):981-986.
31. PONTICELLI C, RIZZONI G, EDEFONTI A et al.: A randomized trial of cyclosporine in steroid-resistant idiopathic nephrotic syndrome. Kidney Int. (1993) 43(6):1377-1384.
32. TUMLIN JA, MILLER D, NEAR M, SELVARAJ S, HENNIGAR R, GUASCH A: A Prospective, Open-Label Trial of Sirolimus in the Treatment of Focal Segmental Glomerulosclerosis. Clin. J. Am. Soc. Nephrol. (2006) 1:109-116.
33. FERVENZA FC, FITZPATRICK PM, MERTZ J et al.: Acute rapamycin nephrotoxicity in native kidneys of patients with chronic glomerulopathies. Nephrol. Dial. Transplant. (2004) 19(5):1288-1292.
34. CHO ME, HURLEY JK, KOPP JB: Sirolimus therapy of focal segmental glomerulosclerosis is associated with nephrotoxicity. Am. J. Kidney Dis. (2007) 49(2):310-317.
35. DU BUF-VEREIJKEN PW, BRANTEN AJ, WETZELS JF: Idiopathic membranous nephropathy: outline and rationale of a treatment strategy. Am. J. Kidney Dis. (2005) 46(6):1012-1029.
36. HOGAN SL, MULLER KE, JENNETTE JC, FALK RJ: A review of therapeutic studies of idiopathic membranous glomerulopathy. Am. J. Kidney Dis. (1995) 25(6):862-875.
37. PONTICELLI C, ZUCCHELLI P, PASSERINI P et al.: A 10-year follow-up of a randomized study with methylprednisolone and chlorambucil in membranous nephropathy. Kidney Int. (1995) 48(5):1600-1604.
38. JINDAL K, WEST M, BEAR R, GOLDSTEIN M: Long-term benefits of therapy with cyclophosphamide and prednisone in patients with membranous glomerulonephritis and impaired renal function. Am J. Kidney Dis. (1992) 19(1):61-67.
39. PONTICELLI C, ZUCCHELLI P, PASSERINI P, CESANA B: Methylprednisolone plus chlorambucil as compared with methylprednisolone alone for the treatment of idiopathic membranous nephropathy. The Italian Idiopathic Membranous Nephropathy Treatment Study Group. N. Engl. J. Med. (1992) 327(9):599-603.
40. CATTRAN DC, APPEL GB, HEBERT LA et al.: Cyclosporine in patients with steroid-rrsistant membranous nepbropathy: a randomized trial. Kidney Int. (2001) 59(4):1484-1490.
41. MUIRHEAD N: Management of idiopathic membranous nephropathy-evidence-based recommendations. Kidney Int. Suppl. (1999) 70:S47-S55.
42. MILLER G, ZIMMERMAN RR, RADHAKRISHNAN J, APPEL G: Use of mycophenolate mofetil in resistant membranous nephropathy. Am J. Kidney Dis. (2000) 36(2):250-256.
43. GOUMENOS DS, AHUJA M, DAVLOUROS P, EL NAHAS AM, BROWN CB: Prednisolone and azathioprine in membranous nephropathy: a 10-year follow-up study. Clin. Ngphrol. (2006) 65(5):317-323.
44. AHUJA M, GOUMENOS D, SHORTLAND JR, GERAKIS A, BROWN CB: Does immunosuppression with prednisolone and azathioprine alter the progression of idiopathic membranous nephropathy? Am. J. Kidney Dis. (1999) 34(3):521-529.
45. DONADIO JV Jr, ANDERSON CF, MITCHELL JC III et al.: Membranoproliferative glomerulonephritis. A prospective clinical trial of platelet-inhibitor therapy. N. Engl. J. Med. (1984) 310(22):1421-1426.
46. KINO T, HATANAKA H, MIYATA S et al.: FK-506, a novel immunosuppressant isolated from a Streptomyces. II. Immunosuppressive effect of FK-506 in vitro. J. Antibiot. (Tokyo) (1987) 40(9):1256-1265.
47. KINO T, HATANAKA H, HASHIMOTO M et al.: FK-506, a novel immunosuppressant isolated from a Streptomyces. I. Fermentation, isolation, and physico-chemical and biological characteristics. J. Antibiot. (Tokyo) (1987) 40(9):1249-1255.
48. OCHIAI T, NAKAJIMA K, NAGATA M et al.: Effect of a new immunosuppressive agent, FK 506, on heterotopic cardiac allotransplantation in the rat. Transplant. Proc. (1987) 19 (1 Part 2):1284-1286.
49. ELLIS D: Clinical use of tacrolimus (FK-506) in infants and children with renal transplants. Pediatr.Nephrol. (1995) 9(4):487-494.
50. LASKOW DA, NEYLAN JF III, SHAPIRO RS, PIRSCH JD, VERGNE-MARINI PJ, TOMLANOVICH SJ: The role of tacrolimus in adult kidney transplantation: a review. Clin. Transplant. (1998) 12(6):489-503.
51. TEPEL M, BACHMANN J, SCHLUTER H, ZIDEK W. Diadenosine polyphosphates increase cytosolic calcium and attenuate angiotensin-II-induced changes of calcium in vascular smooth muscle cells. J. Vase. Res. (1996) 33(2):132-138.
52. BRAM RJ, HUNG DT, MARTIN PK, SCHREIBER SL, CRABTREE GR: Identification of the immunophilins capable of mediating inhibition of signal transduction by cyclosporin A and FK506: roles of calcineurin binding and cellular location. Mol. Cell Biol., (1993) 13(8):4760-4769.
53. SCHREIBER SL, LIU J, ALBERS MW et al.: Immunophilin-ligand complexes as probes of intracellular signaling pathways. Transplant. Proc. (1991) 23(6):2839-2844.
54. SIEKIERKA JJ, HUNG SH, POE M, LIN CS, SIGAL NH: A cytosolic binding protein for the immunosuppressant FK506 has peptidyl-prolyl isomerase activity but is distinct from cyclophilin. Nature (1989) 341(6244):755-757.
55. KAPTURCZAK MH, MEIER-KRIESCHE HU, KAPLAN B: Pharmacology of calcineurin antagonists. Transplant. Proc. (2004) 36(Suppl. 2):25S-32S.
56. FRANTZ B, NORDBY EC, BREN G et al.: Calcineurin acts in synergy with PMA to inactivate I κ B/MAD3, an inhibitor of NF-κB. EMBO J. (1994) 13(4):861-870.
57. +-ATPase activity in renal tubule cells. Proc. Natl. Acad. Sci. USA (1992) 89(16):7394-7397.
58. DAWSON TM, STEINER JP, DAWSON VL, DINERMAN JL, UHL GR, SNYDER SH: Immunosuppressant FK506 enhances phosphorylation of nitric oxide synthase and protects against glutamate neurotoxicity. Proc. Natl. Acad. Sci. USA (1993) 90(21):9808-9812.
59. SAWADA S, SUZUKI G, KAWASE Y, TAKAKU F: Novel inummosuppressive agent, FK506. In vitro effects on the cloned T cell activation. J. Immunol. (1987) 139(6):1797-803.
60. DUMONT FJ, STARUCH MJ, KOPRAK SL, MELINO MR, SIGAL NH: Distinct mechanisms of suppression of murine T cell activation by the related macrolides FK-506 and rapamycin. J. Immunol. (1990) 144(1):251-258.
61. LIN CS, BOLTZ RC, SIEKIERKA JJ, SIGAL NH: FK-506 and cyclosporin A inhibit highly similar signal transduction pathways in human T lymphocytes. Cell. Immunol. (1991) 133(2):269-284.
62. TOCCI MJ, MATKOVICH DA, COLLIER KA et al.: The immunosuppressant FK506 selectively inhibits expression of early T cell activation genes. J. Immunol., (1989) 143(2):718-726.
63. MOHAMED MA, ROBERTSON H, BOOTH TA, BALUPURI S, KIRBY JA, TALBOT D: TGF-β expression in renal transplant biopsies: a comparative study between cyclosporin-A and tacrolimus. Transplantation (2000) 69(5):1002-1005.
64. VENKATARAMANAN R, JAIN A, WARTY VS et al.: Pharmacokinetics of FK 506 in transplant patients. Transplant. Proc. (1991) 23(6):2736-2740.
65. WALLEMACQ PE, VERBEECK RK: Comparative clinical pharmacokinetics of tacrolimus in paediatric: and adult patients. Clin. Pharmacokinet. (2001) 40(4):283-295.
66. NEYLAN JF: Racial differences in renal transplantation after inummosuppression with tacrolimus versus cyclosporine. FK506 Kidney Transplant Study Group. Transplantation (1998) 65(4):515-523.
67. NEYLAN JF: Effect of race and immunosuppression in renal transplantation: three-year survival results from a US multicenter, randomized trial. FK506 Kidney Transplant Study Group. Transplant. Proc. (1998) 30(4):1355-1358.
68. JAIN AB, VENKATARAMANAN R, CADOFF E et al.: Effect of hepatic dysfunction and T tube clamping on FK 506 pharmacokinetics and trough concentrations. Transplant. Proc. (1990) 22(1):57-59.
69. JUSKO WJ, D'AMBROSIO R: Monitoring FK 506 concentrations in plasma and whole blood. Tansplant. Proc. (1991) 23(6):2732-2735.
70. KAY JE, SAMPARE-KWATENG E, GERAGHTY F, MORGAN GY: Uptake of FK 506 by lymphocytes and erythrocytes. Transplant. Proc. (1991) 23(6):2760-2762.
71. KELLY P, KAHAN BD: Review: metabolism of immunosuppressant drugs. Curr. Drug Metab. (2002) 3(3):275-287.
72. JAIN AB, FUNG JJ, TZAKIS AG et al.: Comparative study of cyclosporine and FK 506 dosage requirements in adult and pediatric orthotopic liver transplant patients. Transplant. Proc. (1991) 23(6):2763-2766.
73. MCCAULEY J, TZAKIS AG, FUNG JJ, TODO S, STARZI, TE: FK 506 in steroid-resistant focal sclerosing glomenrulonephritis of childhood. Lancet (1990) 335(8690):674.
74. PENNESI M, GAGLIARDO A, MINISINI S: Effective tacrolimus treatment in a child suffering from severe nephrotic syndrome. Pediatr. Nephrol. (2003) 18(5):477-478.
75. TSUGAWA K, TANAKA H, NAKAHATA T, ITO E: Effiective therapy of a child case of refractory nephrotic: syndrome with tacrolimus. Tohoku J. Exp. Med. (2004) 204(3):237-241.
76. BRATIA M, KHER K, MINNITI CP: Acute lymphoblastic leukemia in a child with nephrotic syndrome. Pediatr. Nephrol. (2004) 19(11):1290-1293.
77. PANDIRIKKAL VB, JAIN M, GULATI S: Tacrolimus-induced HUS: an unusual cause of acute renal failure in nephrotic syndrome. Pediatr. Nephrol. (2007) 22(2):298-300.
78. BENZ K, DOTSCH J, RASCHER W, STACHEL D: Change of the course of steroid-dependent nephrotic syndrome after rituximab therapy. Pediatr. Nephrol. (2004) 19(7):794-797.
79. OSUGI Y, YAMADA H, HOSOI G et al.: Treatment with candesartan combined with angiotensin-converting enzyme inhibitor for immunosuppressive treatment-resistant nephrotic syndrome after allogeneic stem cell transplantation. Int. J. Hematol. (2006) 83(5):454-458.
80. DITTRICH K, KNERR I, RASCHER W, DOTSCH J: Transient insulin-dependent diabetes mellitus in children with steroid-dependent idiopathic nephrotic syndrome during tacrolimus treatment. Pediatr. Nephrol. (2006) 21(7):958-961.
81. LOEFFLER K, GOWRISHANKAR M, YIU V: Tacrolimus therapy in pediatric patients with treatment-resistant nephrotic: syndrome. Pediatr. Nephrol. (2004) 19(3):281-287.
82. SINHA MD, MACLEOD R, RIGBY E, CLARK AG: Treatment of severe steroid-dependent nephrotic syndrome(SDNS) in children with tacrolimus. Nephrol. Dial. Transplant. (2006) 21(7):1848-1854.
83. SCHWEDA F, LIEBL R, RIEGGER GA, KRAMER BK: Tacrolimus treatment for steroid- and cyclosporin-resistant minimal-change nephrotic syndrome. Nephrol. Dial. Transplant. (1997) 12(11):2433-2435.
84. TANG S, TANG AW, TAM MK, HO YW: Use of tacrolimus in steroid- and cyclophosphamide-resistant minimal change nephrotic syndrome. Am. J. Kidney Dis. (2003) 42(5):E13-E15.
85. PATEL P, PAL S, ASHLEY C, SWENY P, BURNS A: Combination therapy with sirolimus (rapanaycin) and tacrolimus (FK-506) in treatment of refractory minimal change nephropathy, a clinical case report. Nephrol. Dial. Transplant. (2005) 20(5):985-987.
86. KUHN C, KUHN A, MARKAU S, KASTNER U, OSTEN B: Effect of immmunoadsorption on refractory idiopathic focal and segmental glomerulosclerosis. J. Clin. Apher. (2006) 21(4):266-270.
87. CHANDRA M, SUSIN M, ABITBOL C: Remission of relapsing childhood nephrotic syndrome with mycophenolate mofetil. Pediatr. Nephrol. (2000) 14(3):224-226.
88. KESSLER M, CHAMPIGNEULLES J, HESTIN D, FRIMAT L, RENOULT E: A renal allograft recipient with late recurrence of focal and segmental glomerulosclerosis after switching from cyclosporine to tacrolimus. Transplantation (1999) 67(4):641-643.
89. MCCAULEY J, SHAPIRO R, ELLIS D, IGDAL H, TZAKIS A, STARZL TE: Pilot trial of FK 506 in the management of steroid-resistant nephrotic syndrome. Nephrol. Dial. Transplant. (1993) 8(11):1286-1290.
90. SEGARRA A, VILA J, POU L et al.: Combined therapy of tacrolimus and corticosteroids in cyclosporin-resistant or -dependent idiopathic focal glomerulosclerosis: a preliminary uncontrolled study with prospective follow-up. Nephrol. Dial. Transplant. (2002) 17(4):655-662.
91. DUNCAN N, DHAYGUDE A, OWEN J et al.: Treatment of focal and segmental glomerulosclerosis in adults with tacrolimus monotherapy. Nephrol. Dial. Transplant. (2004) 19(12):3062-3067.
92. WESTHOFF TH, SCHMIDT S, ZIDEK W, BEIGE J, VAN DER GIET M: Tacrolimus in steroid-resistant and steroid-dependent nephrotic syndrome. Clin. Nephrol. (2006) 65(6):393-400.
93. MIAO L, SUN J, YUAN H, JIA Y, XU Z: Combined therapy of low-dose tacrolimus and prednisone in nephrotic syndrome with slight mesangial proliferation. Nephrology (Carlton) (2006) 11(5):449-454.
94. XIA Z, LIU G, GAO Y et al.: FK506 in the treatment of children with nephrotic syndrome of different pathological types. Clin. Nephrol. (2006) 66(2):85-88.
95. BHIMMA R, ADHIKARI M, ASHARAM K, CONNOLLY C: Management of steroid-resistant focal segmental glomerulosclerosis in children using tacrolimus. Am. J. Nephrol. (2006) 26(6):544-551.
96. VAN HOOFF JP, CHRISTIAANS MH, VAN DUIJNHOVEN EM: Tacrolimus and posttransplant diabetes mellitus in renal transplantation. Transplantation (2005) 79(11):1465-1469.
97. OFFERMANN G: Immunosuppression for long-term maintenance of renal allograft function. Drugs (2004) 64(12):1325-1338.
98. STEELE JA, CHOI C, KWONG PC: Topical tacrolimus in the treatment of inverse psoriasis in children. J. Am. Acad. Dermatol. (2005) 53(4):713-716.
99. AMBALAVANAN S, FAUVEL JP, SIBLEY RK, MYERS BD: Mechanism of the antiproteinuric effiect of cyclosporine in membranous nephropathy. J. Am. Soc. Nephrol. (1996) 7(2):290-298.
100. CHEN D, JEFFERSON B, HARVEY SJ et al.: Cyclosporine a slows the progressive renal disease of alport syndrome(X-linked hereditary nephritis): results from a canine model. J. Am Soc. Nephrol. (2003) 14(3):690-698.